merger « Science and Enterprise

Cell Biology Tools Companies Merge in $57.8M Deal

By Alan, on December 22nd, 2022%

Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation. . . . → Read More: Cell Biology Tools Companies Merge in $57.8M Deal

Mental Health VR Companies Merge, Raise $13M

By Alan, on December 13th, 2022%

Two developers of virtual reality therapy technology for mental health disorders are combining their operations, and raising $13 million in venture funds. . . . → Read More: Mental Health VR Companies Merge, Raise $13M

Gut-Brain Meds Developer Going Public in Merger

By Alan, on October 31st, 2022%

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Immune Disease Biotech Acquired in $405M Deal

By Alan, on August 4th, 2022%

A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences. . . . → Read More: Immune Disease Biotech Acquired in $405M Deal

Ginkgo Acquires Biomaterials Maker as Industry Consolidates

By Alan, on July 25th, 2022%

A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates. . . . → Read More: Ginkgo Acquires Biomaterials Maker as Industry Consolidates

Diabetes Cell Therapy Biotech Acquired in $320M Deal

By Alan, on July 11th, 2022%

A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals. . . . → Read More: Diabetes Cell Therapy Biotech Acquired in $320M Deal

GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

By Alan, on May 31st, 2022%

Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

Partnership Developing Faster, Sensitive Covid-19 Test

By Alan, on May 4th, 2022%

A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test

Digital Mental Therapy Company to Go Public in Merger

By Alan, on January 26th, 2022%

A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger

Novo Nordisk Buys RNA Biotech in $3.3B Deal

By Alan, on November 18th, 2021%

Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal

Subscribe for email alerts

Donate to Science & Enterprise

Like us on Facebook

S&E on Mastodon

S&E on LinkedIn

Posts RSS feed

Specials

Guest Posts

Please share Science & Enterprise